A phase II, multicenter, randomized, double-blind clinical trial to evaluate the efficacy and safety of Tarceva [erlotinib] in combination with Avastin [bevacizumab] versus Avastin alone for treatment of metastatic renal cell carcinoma

Trial Profile

A phase II, multicenter, randomized, double-blind clinical trial to evaluate the efficacy and safety of Tarceva [erlotinib] in combination with Avastin [bevacizumab] versus Avastin alone for treatment of metastatic renal cell carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs Erlotinib (Primary) ; Bevacizumab
  • Indications Renal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 09 Sep 2009 Planned number of patients (100) added as reported by ClinicalTrials.gov.
    • 09 Sep 2009 Planned number of patients (100) added as reported by ClinicalTrials.gov.
    • 10 Oct 2007 Results have been published.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top